Neuro

Synaptive Medical Welcomes Chris Marrus as New Chief Commercial Officer

Retrieved on: 
Thursday, February 29, 2024

Chris Marrus brings extensive experience in innovative med tech to Synaptive having held senior leadership roles at INSIGHTEC, Stryker, MAKO Surgical, Intuitive Surgical and Leica

Key Points: 
  • Chris Marrus brings extensive experience in innovative med tech to Synaptive having held senior leadership roles at INSIGHTEC, Stryker, MAKO Surgical, Intuitive Surgical and Leica
    TORONTO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Synaptive Medical Inc., a global med tech and technology company solving surgical, imaging and data challenges, is proud to announce the appointment of Chris Marrus as Chief Commercial Officer.
  • Chris has a proven track record of spearheading sales initiatives and fostering exponential growth for innovative companies.
  • "Synaptive is thrilled to welcome Chris Marrus to our senior leadership team," stated Cameron Piron, Chief Strategy Officer, President and Founder of Synaptive Medical.
  • "I am thrilled to embark on this journey with Synaptive Medical," commented Chris Marrus, newly appointed Chief Commercial Officer of Synaptive Medical.

Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance

Retrieved on: 
Wednesday, February 28, 2024

PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • Adjusted EBITDA for the fourth quarter of 2023 was $100.5 million, compared to $109.7 million in the fourth quarter of the prior year.
  • Cash flows from operations totaled $58.7M million in the fourth quarter and capital expenditures were $24.6M million.
  • ET on Wednesday, February 28, 2024, to discuss fourth quarter and full-year 2023 financial results, and forward-looking financial guidance.

Philips launches new Azurion neuro biplane system at #ECR2024 to speed up and improve minimally invasive diagnosis and treatment of neurovascular patients

Retrieved on: 
Tuesday, February 27, 2024

As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.

Key Points: 
  • As healthcare providers strive to deliver high-quality care to patients, at #ECR2024 Philips is partnering with its customers to improve productivity and access to more sustainable healthcare.
  • Minimally invasive procedures enabled by interventional systems like Azurion are a key part of the diagnosis and treatment pathway for stroke, where every minute counts in conserving the patient’s quality-of-life.
  • Interventional systems are also used to precisely plan and carry out complex neurovascular procedures such as the repair of brain aneurysms and birth defects.
  • By allowing neuro interventionists to treat more patients, more efficiently, with potentially better outcomes, the new Philips Azurion neuro biplane system enhances both the staff and patient experience and contributes to lower cost of care.

Latest Holistic Approach for those Struggling With Chemical Dependency

Retrieved on: 
Friday, February 23, 2024

The effects of this active metabolite begin to peak within a week after treatment, based upon past patients’ reports of improved cognitive functioning.

Key Points: 
  • The effects of this active metabolite begin to peak within a week after treatment, based upon past patients’ reports of improved cognitive functioning.
  • Informative data stems from metabolic data collected before ibogaine treatment and once more in the days to follow.
  • Results from twenty patients indicate smooth stabilization, indicating safety and efficacy of the active metabolite.
  • Thorough monitoring is crucial for sustained success, but the long-term effectiveness of noribogaine necessitates follow-up updates in subsequent months.

Teva and Jiangsu Nhwa Forge Strategic Partnership to Promote Patient Access to AUSTEDO® in China

Retrieved on: 
Monday, February 26, 2024

The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.

Key Points: 
  • The partnership intends to increase patients’ access to Teva’s AUSTEDO, leveraging Nhwa’s leadership in China’s neuro-psychiatric health sector.
  • “Nhwa has deep neuro-psychiatry expertise and capabilities, from research and development to commercialization,” commented Theodor Wee, General Manager of Teva Greater China.
  • Chorea, one of the most striking physical manifestations of Huntington’s disease, is a neurological disorder that causes involuntary, random muscle movements.
  • Jiangsu Nhwa Pharmaceutical Co., Ltd., founded in 1978, is a leading CNS company in China.

Global Iontronics Market Assessment Report 2023: IP Landscape Analysis, Key Research, Commercial prospects, Technology Roadmap - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 20, 2024

This market assessment report provides a comprehensive analysis of the emerging iontronics technology market.

Key Points: 
  • This market assessment report provides a comprehensive analysis of the emerging iontronics technology market.
  • The report covers key technical aspects including materials, devices like memristors and sensors, and fabrication methods.
  • Commercial prospects are evaluated with addressable market size forecasts across segments, SWOT analysis, and a technology roadmap.
  • The report helps materials suppliers, device manufacturers, electronics OEMs, investors and researchers gain a holistic understanding of the iontronics technology landscape and ecosystem.

Evolution Optiks Secures CE Marking for Groundbreaking Eye Care Device

Retrieved on: 
Thursday, March 7, 2024

CHRIST CHURCH, Barbados, March 7, 2024 /PRNewswire/ -- Evolution Optiks Limited, a privately held company specializing in light field technology, today announced the CE marking under the European Medical Device Regulation of its Tele-Refractor LFR-260 by its wholly-owned subsidiary Evolution Optiks (Europe) Limited, based in Liechtenstein. This is a major milestone that will enable the company to launch its plans to commercialize the disruptive device in the European Economic Area (EEA) and other CE mark countries. The LFR-260 is intended to be used for distance vision testing to evaluate the visual refractive state of the patient.

Key Points: 
  • CHRIST CHURCH, Barbados, March 7, 2024 /PRNewswire/ -- Evolution Optiks Limited , a privately held company specializing in light field technology, today announced the CE marking under the European Medical Device Regulation of its Tele-Refractor LFR-260 by its wholly-owned subsidiary Evolution Optiks (Europe) Limited, based in Liechtenstein.
  • Technically, the CE marking indicates that a product complies with all relevant EU directives and regulations concerning health, safety, and environmental protection standards.
  • But beyond that, the CE marking is the culmination of a journey that the team of Evolution Optiks began in 2018 when they set out to revolutionize the way eye exams are done.
  • Founded in 2014, Evolution Optiks Limited is commercializing an extensive and ongoing portfolio of innovation and is on track to revolutionizing how digital information is being consumed.

Evolution Optiks Secures CE Marking for Groundbreaking Eye Care Device

Retrieved on: 
Thursday, March 7, 2024

CHRIST CHURCH, Barbados, March 7, 2024 /PRNewswire/ -- Evolution Optiks Limited, a privately held company specializing in light field technology, today announced the CE marking under the European Medical Device Regulation of its Tele-Refractor LFR-260 by its wholly-owned subsidiary Evolution Optiks (Europe) Limited, based in Liechtenstein. This is a major milestone that will enable the company to launch its plans to commercialize the disruptive device in the European Economic Area (EEA) and other CE mark countries. The LFR-260 is intended to be used for distance vision testing to evaluate the visual refractive state of the patient.

Key Points: 
  • CHRIST CHURCH, Barbados, March 7, 2024 /PRNewswire/ -- Evolution Optiks Limited , a privately held company specializing in light field technology, today announced the CE marking under the European Medical Device Regulation of its Tele-Refractor LFR-260 by its wholly-owned subsidiary Evolution Optiks (Europe) Limited, based in Liechtenstein.
  • Technically, the CE marking indicates that a product complies with all relevant EU directives and regulations concerning health, safety, and environmental protection standards.
  • But beyond that, the CE marking is the culmination of a journey that the team of Evolution Optiks began in 2018 when they set out to revolutionize the way eye exams are done.
  • Founded in 2014, Evolution Optiks Limited is commercializing an extensive and ongoing portfolio of innovation and is on track to revolutionizing how digital information is being consumed.

New neuro-symbolic AI chat to disrupt $650bn GCC wealth management market

Retrieved on: 
Friday, March 1, 2024

ZURICH and DUBAI, UAE, March 1, 2024 /PRNewswire/ -- Latest advancements in neuro-symbolic AI is poised to further disrupt the wealth management industry with a new generation of portfolio management tools, with reporting, personalization and industry-leading data accuracy.

Key Points: 
  • WealthArc, a Swiss-born global wealth data management solution provider, has partnered with ZeroLink, a pioneering company in neuro-symbolic AI technology, to develop the cutting-edge machine learning-powered 'Chat with your data' service, and hopes to target family offices and the wealth management market across the GCC with AuM worth US$650 billion.
  • WealthArc has been empowering family offices, wealth managers, private banks and other wealth owners with the state-of-the-art data management platform aggregating more than 200k positions every day across the globe.
  • The multi-custodian and multi-currency driven solution is intuitive, easy to use and customizable, with a high level of data quality.
  • "The solution developed together with ZeroLink will revolutionize the way family offices, portfolio managers, as well as wealth owners, interact with wealth data, raising the bar for the wealth management space as a whole," says Radomir Mastalerz, CEO of WealthArc.

HSS Orthopedics with Stamford Health Establishes Premier Spine Center in Connecticut

Retrieved on: 
Monday, February 26, 2024

STAMFORD, Conn., Feb. 26, 2024 /PRNewswire/ -- Back pain is a complex, widespread issue across the United States, with the Centers for Disease Control and Prevention estimating that 65 million Americans are affected. Common reasons include arthritis, disc and nerve injury, muscle strain, and other underlying health conditions such as osteoporosis and scoliosis. Responding to the urgent need for increased access to high quality spine care in Connecticut, a specialist center was created last year as an extension of the collaboration between Hospital for Special Surgery (HSS) and Stamford Health.

Key Points: 
  • Responding to the urgent need for increased access to high quality spine care in Connecticut, a specialist center was created last year as an extension of the collaboration between Hospital for Special Surgery (HSS) and Stamford Health.
  • The HSS Spine Center with Stamford Health led by co-medical directors Steven J. McAnany, MD , spine surgeon at HSS, and Andrea F. Douglas, MD, FAANS, FACS , chief of Neurosurgery at Stamford Health, builds on a successful collaboration started in 2016.
  • "The HSS Spine Center with Stamford Health harnesses the expertise of our respective institutions to bring world-class patient care to the communities we serve," said Kathleen Silard, president and CEO at Stamford Health.
  • "Over the past year, hundreds of patients with back and neck conditions have benefitted from the exceptional capabilities and proven expertise we offer through the HSS Spine Center with Stamford Health."